Repligen Q4 EPS of $0.44 beat the $0.41 estimate, while revenue of $167.55 million was in line with forecasts. 2025 sales guidance set at $685 million–$710 million ...
The company raised the midpoint of its revenue growth guidance, now expecting 14% to 15.5% organic non-COVID growth or 12% to 13.5% organic revenue growth for 2025, with the midpoint of both ...
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The ...
Repligen Corporation (NASDAQ:RGEN), a $9.36 billion market cap leader in bioprocessing technology, has been navigating a complex market landscape characterized by innovation, strategic acquisitions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results